KRT18 and infection: Our data demonstrated that two doses of either 3 μg or 6 μg of the ERUCoV-VAC elicited strong immune responses and fully protected K18-hACE2 mice from morbidity and mortality, whereas mice vaccinated with PBS succumbed to infection within 6 days (Figure 3c).